The diagnostic ability of serum exo-AnxA2 was also evaluated in ER+ (n = 50), HER2+ (n = 59), and TNBC (n = 58) patients compared to non-cancer (n = 68) patients. This evidence concerns the gene ANXA2 and cancer.